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Sarcoidosis is a chronic relapsing multi-systemic disorder
characterized by the development of non-caseating
granulomas. Granulomatous tubulo-interstitial nephritis is
an uncommon manifestation of this condition. We identified
39 patients with sarcoidosis and renal disease from a
single center of whom 17 patients had biopsy-proven
tubulo-interstitial nephritis. They were analyzed with respect
to demographic and clinical features, including response to
corticosteroids and length of follow-up. They all presented
with significant renal impairment. At presentation the
mean7s.d. estimated glomerular filtration rate (eGFR) was
26.8714 ml/min by modification of diet in renal disease
(MDRD) equation 7. With treatment there was a significant
improvement in renal function with eGFR 49.675.2 ml/min
(Po0.01) at 1 year, and 47.976.8 ml/min (Po0.05) at the last
review. The median follow-up was 84 months (range 6–284
months). Patients with chronic kidney disease (CKD) 3, the
mean eGFR was 38.3072.4 ml/min at presentation and
60.277.4 ml/min at 1 year (P¼ 0.02) and in CKD 4 it
improved from 1972 to 3876.6 ml/min at 1 year (Po0.05).
After the 1st year, the change in eGFR was þ 0.8 ml/min/year
for CKD 3 and 2 ml/min/year for CKD 4 (Po0.05). Three
patients ceased their therapy either due to complications or
poor compliance and experienced a worsening of renal
function which was then reversed on re-commencing
corticosteroids. Corticosteroids are effective in advanced
tubulo-interstitial nephritis due to sarcoidosis. Long-term
treatment is necessary to preserve renal function and to
delay the onset of end-stage renal disease.
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Sarcoidosis is a multi-systemic disorder characterized by the
development of non-caseating granulomas. Typically, it
presents in adulthood and is more common amongst black
patients, who have a 2.4% lifetime risk of developing the
disease.1 The etiology is unclear though infectious agents,
occupational exposure to organic and inorganic agents,
autoimmunity, and genetic factors have been implicated.2
The illness may be self-limiting or chronic, with episodic
recrudescence and remissions. The majority of patients
present with systemic symptoms, with respiratory involve-
ment occurring at some time in the course of disease in
virtually all patients. Renal manifestations of sarcoidosis are
most commonly due to disorders in calcium homeostasis.
Hypercalciuria is common and is present in up to half of
patients with sarcoidosis, but overt hypercalcemia is only a
feature in approximately 10% of patients, leading to renal
impairment in some.3 Granulomatous tubulo-interstitial
nephritis (TIN), a diagnosis only made at biopsy, is a less
common cause of renal impairment and is often accom-
panied by systemic manifestations,4 although it has been
described in the absence of extrarenal sarcoid in a small case
series.5 There is some evidence that subclinical TIN is present
in between 7 and 27% of all patients from post-mortem
series, but has not been thought to contribute greatly to
clinical sequelae.6 Alternative causes such as drugs and
tuberculosis (TB) must be excluded from the differential
diagnosis.7
The mainstay of treatment in an acute setting has been
corticosteroids with a good success rate,5,8,9 There is however
a paucity of data on the impact of maintenance therapy to
long-term outcome, the risk of relapse and progression of
chronic kidney disease (CKD). We present the largest single
center series of biopsy-proven TIN due to sarcoidosis that
were treated and maintained on corticosteroids.
RESULTS
Patients
Thirty nine patients were assessed by the renal unit between
January 1982 and December 2004 with sarcoidosis and
significant renal disease. Twenty patients (51.2%) underwent
a renal biopsy. Of the remaining 19 patients, four patients
had presented with hypercalcemia with either nephro-
calcinosis or overt calculi on screening. The remaining
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non-biopsied patients not in end-stage renal failure either
had an alternative diagnosis or had mild stable chronic renal
impairment (CKD 1/2) with no indication for renal biopsy
(Figure 1).
Of the twenty patients who underwent a renal biopsy, 17
were diagnosed with TIN. All patients with TIN had evidence
of systemic sarcoidosis of which nine cases had a previous
history of extrarenal sarcoid with median disease duration of
4 years (range 3 months–14 years). The remaining eight
patients were either referred by their family practitioner or
presented to the accident and emergency department with
unexplained renal impairment and were subsequently
diagnosed with TIN and systemic sarcoid. Only two of the
eight patients were on corticosteroids at the time of
diagnostic biopsy both of whom had stage 4 lung disease.
Three patients presenting with nephrotic range proteinuria
had a primary glomerular lesion with no interstitial
involvement (Figure 1). Of those with interstitial nephritis,
eight patients were male and nine female, with a mean age of
44715 years. Nine patients (53%) were of afro-Caribbean
origin and six were Caucasian (35%). Demographics and
clinical presentation, with estimated glomerular filtration
rate (eGFR) are summarized in Table 1. Renal function in all
patients at the time of diagnosis was severely impaired, with
mean eGFR 26.8714 ml/min. Eight patients (47%) had
preceding pulmonary involvement, with confirmation on
chest X-ray or high-resolution computed tomography of
the chest. Serum angiotensin-converting enzyme (ACE) level
was only elevated in three patients at the time of diagnosis.
Two patients presented with an acute systemic illness with
severe renal impairment. There were no cases with renal
limited granulomatous TIN in this series. Early morning
urine cultures and Ziel–Nielsen staining were negative in
all cases.
Sarcoidosis and
renal disease,
n=39
n=19
n=7
n=4
n=1
n=1
n=1
n=1 n=1
n=1
Native renal biopsy,
n=20
(51.2%)
No renal biopsy,
(48.8%)
TIN,
n=17
Glomerular dise-
ase with no TIN,
n=3 n=3 n=4 n=5
ESRF
(small kidneys),
Hypercalcaemia/
nephrocalcinosis,
CKD 1-2 with sta-
ble renal function,
Other,
Reflux,
Diabetes
[presumed],
NSAIDS*,
RPF,
FSGS,
Minimal change,
IgA,
Figure 1 | The diagnostic breakdown of all patients referred to the Barts and the London Hospital renal unit with sarcoidosis and renal
disease. * Patient presented with acute renal failure secondary to non-steroidal anti-inflammatory drugs which resolved on discontinuation
of the drug hence a kidney biopsy was not performed. TIN: tubulo-interstitial nephritis; FSGS: primary focal segmental glomerulosclerosis;
RPF: retroperitoneal fibrosis.
Table 1 | Demographics of patients with confirmed sarcoid
interstitial nephritis on renal biopsy
%
Age 44715.8
Sex
Male 8 47
Female 9 53
Race
Black 9 53
White 6 35
Indo-Asian 2 12
Clinical features
Chest 8 47
Lymph nodes 4 24
Uveitis 6 35
Hypercalcemia 4 24
Elevated SACE 3 18
Creatinine (mean7s.d.) 3667299mmol/l
eGFR (mean7s.d.) 26.8714 ml/min
Follow-up (mean7s.d.) 88773
SACE, serum angiotensin-converting enzyme; eGFR, estimated glomerular filtration
rate; s.d., standard deviation.
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Histology
The typical histological appearances of granulomatous
interstitial nephritis on renal biopsy are shown in Figure 2.
Glomeruli were normal except in two patients of whom one
had membranous glomerulonephritis with granulomatous
TIN. In the other there were changes consistent with steroid-
induced diabetes mellitus as the biopsy was carried out late in
the course of sarcoidosis. There was no correlation between
presenting creatinine and the degree of tubular atrophy
(Spearman’s r¼ 0.045, P¼NS). All patients had evidence of
tubular fibrosis on renal biopsy. Granulomas were present in
all but four cases. Three of the patients with no granulomas
had advanced scarring, normal serum calcium, extrarenal
sarcoid and a steroid-responsive course. Five patients had
evidence of intracellular calcification, but this was not
associated with elevated serum calcium in four patients.
The presence of intracellular calcium was not associated with
differences in either presenting renal function or response to
corticosteroids.
Treatment
All patients were initially treated with prednisolone at a
starting dose of 0.5 mg/kg body weight which approximated to
a daily dose of 30–60 mg daily. Mean eGFR in patients with
TIN was 26.8714 ml/min. All patients showed a beneficial
response to prednisolone within the 1st year (Figure 3a) with
median follow-up of 84 months (range 6–264 months). All
patients irrespective of the stage of CKD showed a satisfactory
response to treatment with an improvement of mean eGFR
from 26.8714 to 49.675.2 ml/min (Po0.01) at 1 year, and
47.976.8 ml/min (Po0.05) at last follow-up (Figure 3b).
In patients presenting with stage 3 CKD, the mean eGFR
was 38.372.4 ml/min at presentation and 60.277.4 ml/min
at 1 year (P¼ 0.02), and in stage 4 CKD mean eGFR
improved from 1972 to 3876.6 ml/min at 1 year (Po0.05).
There was no difference in the response to treatment between
black and non-black patients. There was a satisfactory
response to corticosteroids irrespective of the degree of
tubulo-interstitial scarring with significant improvement in
eGFR at 1 year in patients with grade 2 and 3 changes on
biopsy (Figure 4).
We then investigated the change in eGFR during the
course of follow-up in different stages of CKD. After the 1st
year, the change in eGFR was þ 0.8 ml/min/year for CKD 3
and 2 ml/min/year for CKD 4 (Po0.05). However, the
mean duration of follow-up in CKD 4 was 137725 months
compared to 66.4719.7 months in CKD 3 (P¼ 0.08).
It was our unit policy to taper the daily prednisolone dose
by 5 mg each week once the renal function has improved and/
or stabilized. The patients are then maintained on 5–7.5 mg
daily indefinitely. Three patients ceased their therapy either
due to side effects or poor compliance and experienced a
significant deterioration in renal function, which was then
reversed on re-commencing corticosteroids. One patient was
lost to follow-up after 11 years with discontinuation of
treatment, and subsequently presented in end-stage renal
failure. The patient with both membranous nephropathy and
TIN was commenced on mycophenolate mofetil in addition
to prednisolone and is maintained on both. Another two
a b
c
Figure 2 | Histological features of sarcoid TIN. (a) There is a diffuse
lymphocytic infiltrate through the interstitium with evidence of
interstitial scarring. (b) There is granuloma adjacent to a normal
glomeruli. (c) The arrow points to an asteroid body an infrequent but
classical feature of sarcoid TIN.
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Figure 3 | Response to corticosteroid treatment. (a) Individual
eGFRs at presentation and at 1 year in patients with sarcoid TIN.
(b) Mean eGFR at presentation, 1 year and at last follow-up in
the same group. The mean eGFR improved from 26.8714 to
49.675.2 ml/min (Po0.01) at 1 year, and 47.976.8 ml/min
(Po0.05) at last follow-up.
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Figure 4 | Correlation of degree of fibrosis with response to
treatment. The degree of tubular atrophy was determined and
graded 0–3 (0, no fibrosis and 3, severe fibrosis) by three investigators
blinded to the patient demographics and clinical presentation.
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patients with multiple relapses as evidenced by a rise in
creatinine were successfully treated with mycophenolate
mofetil and Azathioprin, respectively, as steroid-sparing
agents.
Thirteen patients were treated for hypertension and were
all on either an ACE inhibitor or angiotensin receptor blocker
during the follow-up period. Of this group seven patients
were on one or more additional agents to control blood
pressure. There was a nonsignificant improvement in DGFR/
year in those patients on ACE/angiotensin receptor blocker
(DGFR/year on ACE/angiotensin receptor blocker þ 1.67
3.5 ml/min, not on ACE/angiotensin receptor blocker 0.97
1.7 ml/min, P¼NS). In all but one patient with nephrotic
syndrome, 24 h urinary protein excretion was o0.5 g with
preservation of serum albumin.
Three patients developed side effects that could be
attributed to steroids. One patient developed acute psychosis
with high-dose steroids that responded to a dose reduction.
Two patients developed type 2 diabetes (one, insulin treated
and one, diet controlled).
DISCUSSION
Renal involvement in sarcoidosis is uncommon and patients
often present with significant renal disease to the nephro-
logists late in the course of their disease as reflected by the
presenting eGFR and the presence of tubular atrophy. High-
dose corticosteroid therapy is the established treatment
option for acute granulomatous interstitial nephritis. Its
efficacy in patients with biopsy-proven advanced renal
disease is unclear. In previously published literature,
corticosteroids do appear to have a positive impact on
preventing the progression of advanced renal disease.5 There
is no evidence to dictate the duration of maintenance
therapy. The majority of patients in this series were either
CKD 3 or CKD 4 and in both groups there was a significant
improvement of renal function at 1 year.
Clinical disease in systemic sarcoidosis is highly variable
with a tendency to wax and wane either spontaneously or
with steroids. In the pulmonary sarcoidosis the relapse rate is
20–50% when corticosteroids were stopped.10,11 In advanced
renal disease the discontinuation is likely to lead to
deterioration of renal function which may irreversibly
progress to end-stage renal disease. In this series, low-dose
steroids were maintained with good preservation of renal
function. In those patients presenting to nephrologists in
CKD 4, there was a slow decline of GFR over a prolonged
follow-up of 14 years after the initial improvement, but this
was not dissimilar to the rate observed in age-related decline
of renal function.12 Patients who either discontinued
treatment or were non-compliant developed worsening of
renal function which subsequently improved on recommen-
cing steroids. Only one patient who was not on maintenance
steroids developed end-stage renal disease.
The benefit of long-term steroid use needs to be balanced
against the potential adverse effects. Two patients in our
series developed type 2 diabetes. There is a risk of moderate
reduction in bone mineral density with low-dose main-
tenance steroid therapy.13 Therefore, prophylactic treatment
with bisphosphanates and vitamin D preparations are
indicated. In our unit all patients on maintenance steroids
were commenced on a calcium–vitamin D supplement.
Another option would be the institution of steroid-sparing
agents (mycophenolate mofetil, azathioprin) as practiced in
our unit for patients who relapsed on maintenance steroids.
The differential diagnosis of TIN is extensive with
infections (e.g., TB) and drugs (e.g., antibiotics, non-
steroidal anti-inflammatory agents) should be considered
and excluded. In our series, all patients had systemic evidence
of sarcoidosis of which four did not have the typical feature
of granulomas in the renal biopsy. This is likely to be due to
their advanced disease at presentation or sampling effect. The
response to treatment in the latter mirrored the patients with
granulomatous interstitial nephritis. Two patients had
treatment for TB prior to be diagnosed with sarcoid TIN.
In one patient the TB was never proven but was treated
empirically for chest symptoms as her daughter at the time
was diagnosed with the disease. The second patient
completed a course of treatment for pulmonary TB 9 years
after the diagnosis of respiratory sarcoid. After 4 years sarcoid
TIN was diagnosed with no active evidence of TB. Isoniazid
prophylaxis was given with corticosteroids in both patients
with induction of remission of sarcoid and no reactivation of
TB. Serum ACE levels were raised in only a minority of
patients. It lacks specificity for both the diagnosis and as
a predictor of disease progression.14,15
This series demonstrate that sarcoid interstitial nephritis
typically presents with already advanced renal disease.
Despite this, it is an important diagnosis to confirm, as
there is excellent response to corticosteroid therapy even with
advanced chronic changes on biopsy. Long-term mainte-
nance treatment with low-dose corticosteroids helps to
preserve renal function and prevent the onset of end-stage
renal disease. There is however side effects from maintenance
corticosteroids which need to be balanced against the risk of
progression to end-stage renal disease. The efficacy of steroid-
sparing agents such as mycophenolate mofetil or azathioprin
requires further investigation.
MATERIALS AND METHODS
Patients
We identified 39 patients referred to the Barts and the Royal London
Hospital Renal unit during the period January 1982 to December
2004 with sarcoidosis and renal disease. The indications for renal
biopsy were unexplained progressive renal impairment, proteinuric
renal disease with or without a previous history of sarcoidosis.
Contraindications were overt nephrocalcinosis and small kidneys on
renal imaging. In 20 patients a native renal biopsy was indicated and
technically possible of which 17 patients were diagnosed with TIN.
The breakdown of the whole cohort is in Figure 1. The patients with
TIN were analyzed with respect to epidemiological and clinical
features, including response to therapy with corticosteroids and
length of follow-up. eGFR was calculated by the 4-variable
modification of diet in renal disease equation 7.16
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Histological analysis
Renal biopsy samples were processed in the routine manner and
embedded in paraffin wax. The sections were stained with
hemotoxylin and eosin. All of the specimens were reviewed by
three observers and the changes within glomeruli, tubules,
interstitium, and vessels documented. These included tubulitis,
interstitial inflammation, scarring, and the presence or absence of
calcium deposits and/or granulomas. Tubulo-interstitial scarring
was scored based on the degree of fibrosis in the cortical sample
where scarring in up to 5% of the tissue was graded as 0; 6–25%
fibrosis in the sample was graded 1 (mild); 26–50% graded 2
(moderate), and 450% graded 3 (severe).
Treatment protocol
Once the diagnosis of TIN was made, patients were commenced on
prednisolone 0.5 mg/kg body weight. The starting dose was usually
between 30 and 60 mg daily. Once renal function improved or
stabilized, the daily prednisolone dose was tapered by 5 mg per week
until maintenance dose of 5–7.5 mg was achieved.
Statistics
GraphPad Prism version 3.00 for Windows XP, GraphPad Software,
San Diego, CA, USA was used for the analysis. Mann–Whitney U
and paired t-tests were used to compare year 0 and year 1 eGFR in
different groups. Spearman’s rank coefficient was used to correlate
renal function with interstitial scarring. A P-value of o0.05 was
considered significant.
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